Media headlines about Innocoll (NASDAQ:INNL) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innocoll earned a news impact score of 0.09 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 44.7469577023245 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Innocoll (NASDAQ:INNL) traded up $0.11 on Monday, hitting $2.35. 392,900 shares of the stock traded hands, compared to its average volume of 867,012. The firm has a market cap of $70.73 and a PE ratio of -1.42. The company has a debt-to-equity ratio of -2.26, a current ratio of 1.01 and a quick ratio of 0.86. Innocoll has a 12 month low of $0.53 and a 12 month high of $6.51.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at

About Innocoll

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

Insider Buying and Selling by Quarter for Innocoll (NASDAQ:INNL)

Receive News & Stock Ratings for Innocoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll and related stocks with our FREE daily email newsletter.